Compound ID | 1240

FG-LpxC-UTI

Class: Lipopolysaccharide synthesis inhibitor (LpxC inhibitor)

Spectrum of activity: Gram-negative
Details of activity: Urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilisincluding multi-drug resistant strains
Institute where first reported: Entasis Therapeutics
Highest developmental phase: Preclinical
Development status: Active

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.